The 9th Annual Western Regional International Health Conference (WRIHC), “At a Crossroads: Choosing Hidden Paths in Global Health,” took place on the UW Seattle campus April 27-29, 2012 (www.wirhc.org). Joseph Babigumira presented in two sessions at the conference: “Marginalized Populations: Health: A Human Right?” and “Realities in the Field: When Good Intentions are not Enough” [...]
Graduate Student Assisting with Pharmacy Management in Afghanistan
Graduate student Norio Kasahara, MPH, has been working for the Urban Health Systems Strengthening Project in Afghanistan as Technical Advisor since 2011, which is funded by Japan International Cooperation Agency (JICA). One of the project objectives is to develop capacity of sub-national public health department. As the Afghan Ministry of Public Health prioritizes improvement of the pharmacy management, [...]
Expanded Access to Contraception Provides Economic Benefits to Sub-Saharan African Country
Two papers were recently published highlighting the work of Joseph Babigumira and colleagues on the economic analyses of unsafe abortions and on increasing access to contraception in Uganda. His work used modeling methods to show that unsafe abortions cost the country substantial resources and that providing universal access to modern contraceptives would be highly cost-effective. Recent news stories, such as [...]
Global Medicines Faculty and MSH Offer Pharmacoeconomics Training of Trainers Workshop in South Africa
Lou Garrison and Joseph Babigumira conducted a training of trainers workshop “Applying Pharmacoeconomics to Essential Medicines Selection” April 10-12, 2012 in Johannesburg, South Africa. The workshop was offered in conjunction with Management Sciences for Health (MSH) through the USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. The twenty workshop attendees were mostly [...]
FDA Medwatch Newsfeed
- Zithromax (azithromycin): FDA Statement on risk of cardiovascular death
- Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose
- Hydromorphone Hydrochloride Injection 1 MG/ML, (C-II) 1 ML Fill In 2.5 ML Carpuject: Recall - May Contain More Than the Intended Fill Volume
- Revlimid (lenalidomide): Ongoing Safety Review - Increased Risk of Developing New Malignancies
- Certain Compounded Drugs from Franck's: FDA Issues Second Warning to Physicians
